You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.

    SBC: OAK RIDGE THERAPEUTIC DISCOVERY LLC            Topic: NIA

    Abstract There is an unmet need to develop treatments for senile osteoporosis, a disorder characterized by an age-related reciprocal decrease in osteogenesis and increase in bone marrow fat. Senile osteoporosis resembles disuse osteopenia, suggesting its pathogenesis involves impaired bone mechanosensing. We discovered that the polycystin heterotrimeric complex (1PC1+3PC2) functions as a mechanose ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. CN-105 Improves Functional Outcome After Intracranial Hemorrhage

    SBC: AegisCN LLC            Topic: 106

    Annually, approximately 100,000 patients in the USA suffer from intracerebral hemorrhage (ICH), which is associated with high mortality rates and poor long-term cognitive and physical recovery. At present, no pharmacological therapies have been demonstrated to improve functional outcomes after ICH. However, we have successfully demonstrated that CN-105, a pentapeptide derived from the receptor bin ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. THERAPY FOR ALCOHOL USE DISORDER

    SBC: ARTIAM BIO INC.            Topic: 150

    Abstract Alcohol use disorder (AUD) is a major global health issue. In the US, AUD affects over 14 million people over the age of 18. While there are three approved drugs for AUD, less than 4% of patients eligible for pharmacotherapy are prescribed a medication – likely due to limited efficacy of currently approved agents. Also, the relapse rate for AUD continues to be exceedingly high. Thus, ne ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Live spike sorting for multichannel and high-channel recordings

    SBC: POPNEURON LLC            Topic: 106

    Project Summary: The goal of this project is to create two prototypes of a novel live spike sorting system which can be used by investigators to spike sort streams of neural data recorded by multi-channel, high channel and ultra-high channel probes. In most in-vivo extracellular recording conditions, an electrode can pick up neural spikes from several nearby neurons resulting in so-called “multi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Improving parent-adolescent communication about sexual and reproductive health

    SBC: Teen Health Research, Inc.            Topic: NICHD

    PROJECT SUMMARY Early adolescence, between the ages of 10-13, is a critical time for sexuality development. It is a period when most young people enter puberty and have new questions about bodies, relationships, and sexual activity. However, the majority of US adolescents enter this early adolescent period without access to the kind of inclusive, comprehensive sex education that could help them de ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment

    SBC: SEAK Therapeutics, LLC            Topic: 106

    Project SummaryEpilepsy is one of the most common brain disorders. Current drugs have limited efficacy. Identifying new targeted drugs that can be used as safer, more effective therapies is in urgent unmet need. Selective inhibition of the transient receptor potential canonical 3 (TRPC3) emerges as a novel strategy to impede epilepsy. However, the currently best selective TRPC3 inhibitor, Pyr3, ha ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. An IGF-1R-targeting peptide drug conjugate for targeted treatment of atypical teratoid/rhabdoid tumors

    SBC: NIGHTHAWK BIOSCIENCES, INC.            Topic: 102

    PROJECT SUMMARY Atypical teratoid/rhabdoid tumors (AT/RT) are rare embryonal central nervous system malignancies that occur in early childhood and are lethal. Current treatment strategies for children diagnosed with AT/RT are limited to surgery, radiation, and chemotherapy, but to date, none of these have successfully improved survival beyond 18 months, and most are associated with significant tox ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View

    SBC: YAYA SCIENTIFIC LLC            Topic: NIBIB

    PROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Addressing bone marrow lesions that compromise osteochondral tissue repair

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    ABSTRACT Degenerative joint diseases such as osteoarthritis (OA) remain the source of significant pain and disability, affecting over 30 million adults with an annual US economic burden of more than $486 billion. Joint replacement is a well-established procedure, but its finite life span makes this treatment unacceptable for younger (under 65) or more active individuals. For this growing patient p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Novel Small Molecule Anti-Fibrotic Agent for the Treatment of Systemic Scleroderma

    SBC: APIE THERAPEUTICS INC            Topic: NHLBI

    ABSTRACT The goal of this STTR proposal is to develop a novel anti-fibrotic agent suitable for oral administration which could be used to safely and effectively treat Systemic Sclerosis (SSc), or Systemic Scleroderma patients. SSc is one of the most disabling and lethal immune-mediated rheumatic disorders. SSc is a rare disease, affecting 40,000-150,000 people in the United States and conferring a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government